Trinity Biotech plc (TRIB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $4.96M
Last updated: Nov 17, 2026 at 4:15 PM ET
Trinity Biotech plc (TRIB) Statistics
Trinity Biotech (TRIB) has a market cap of $4.96M and an enterprise value of $137.81M. Its net debt of $132.84M equals 2678.27% of its market cap. It kept -97.33% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 2678.27% above the market cap, as debt exceeds cash.
| Market Cap | $4.96M |
|---|---|
| Enterprise Value | $137.81M |
| Latest price (Nov 17, 2026) | $6.01 |
Key Dates
The next earnings report is expected on Dec 22, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Dec 22, 2026 (expected) |
|---|---|
| Last Earnings Date | Apr 30, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 77.21% over 52 weeks and trades 11.49% below its 50-day average.
| Beta (1Y) | 1.74 |
|---|---|
| 52-Week Change | -77.21% |
| 1-Month Change | -26.62% |
| 3-Month Change | -45.41% |
| 6-Month Change | -64.55% |
| 5-Year Change | -97.98% |
| 10-Year Change | -99.39% |
| Total Return (1Y) | -77.21% |
| Total Return (3Y CAGR) | -52.85% |
| Total Return (5Y CAGR) | -53.95% |
| Return vs SPY (1Y) | -87.23% |
| Max Drawdown (1Y) | -86.09% |
| Max Drawdown (3Y) | -94.85% |
| Sharpe Ratio (1Y) | -1.23 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $6.79 |
| 200-Day Average | $14.31 |
| 52-Week Range | $5.00 to $52.50 |
| RSI (14 Days) | 45.0 |
| Average Volume (20 Days) | 11.30K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.25x current liabilities.
| Current Ratio | 0.25x |
|---|---|
| Quick Ratio | 0.12x |
| Interest Coverage | -0.30x |
Returns and Efficiency
Return on invested capital is -14.34% over the last 12 months, against a 5-year average of -31.12%.
| Return on Assets (ROA) | -35.54% |
|---|---|
| Return on Invested Capital (ROIC) | -14.34% |
| ROA (5Y Average) | -30.10% |
| ROIC (5Y Average) | -31.12% |
| Asset Turnover | 0.46x |
| Inventory Turnover | 1.58x |
| Receivables Turnover | 4.82x |
| Cash Conversion Cycle | 54 days |
Scores
TRIB has an Altman Z-Score of -2.58, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.58 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $47.35M over the last 12 months is down 13.00% from the 12 months before.
| Revenue | $47.35M |
|---|---|
| Revenue Growth (YoY) | -13.00% |
| Gross Profit | $17.51M |
| Operating Income | -$9.47M |
| Pretax Income | -$46.06M |
| Net Income | -$46.08M |
| EBITDA | -$6.69M |
| EBIT | -$9.47M |
| Reported EPS (TTM) | -$1,316.05 |
Trailing 12 months through Mar 31, 2026.
Balance Sheet
| Cash and Equivalents | $5.14M |
|---|---|
| Total Debt | $137.98M |
| Net Debt | $132.84M |
| Working Capital | -$105.31M |
| Shareholder Equity | -$71.98M |
| Tangible Book Value | -$128.97M |
| Total Assets | $105.17M |
| Total Liabilities | $177.15M |
Balance sheet as of Mar 31, 2026.
Cash Flow
After $65.64K of capital spending, operating cash flow left -$4.91M of free cash flow.
| Operating Cash Flow | -$4.85M |
|---|---|
| Capital Expenditures | $65.64K |
| Free Cash Flow | -$4.91M |
| FCF Per Share | -$5.95 |
| Depreciation and Amortization | $2.78M |
Trailing 12 months through Mar 31, 2026.
Margins
The operating margin is -19.99%, against a 5-year average of -25.52%.
| Gross Margin | 36.98% |
|---|---|
| Operating Margin | -19.99% |
| Pretax Margin | -97.28% |
| Net Margin | -97.33% |
| EBITDA Margin | -14.12% |
| EBIT Margin | -19.99% |
| FCF Margin | -10.37% |
| Gross Margin (5Y Average) | 36.82% |
| Operating Margin (5Y Average) | -25.52% |
| Net Margin (5Y Average) | -48.75% |
Growth
Revenue fell 11.20% a year over 3 years.
| Revenue Growth (3Y CAGR) | -11.20% |
|---|---|
| Revenue Growth (5Y CAGR) | -15.56% |
Dividends and Yields
TRIB does not pay a dividend.
| Buyback Yield | -0.06% |
|---|---|
| Shareholder Yield | -0.06% |
Stock Splits
The last split was a 1-for-30 reverse split on Jul 24, 2026.
| Last Split Date | Jul 24, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 7 similar companies, TRIB has the 2nd highest ROIC.
ROICPeer median -147.05%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +46.22%
| ROIC | -14.34% vs -147.05% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -13.00% vs +46.22% median |
Analyst Forecast
Consensus estimates put revenue growth at 35.89% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +35.89% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TRIB
What is TRIB's market cap?
Trinity Biotech has a market cap of $4.96M. Its enterprise value, which adds debt and subtracts cash, is $137.81M.
How many shares of TRIB are outstanding?
Trinity Biotech has 620.90K shares outstanding. The count is up 1.80% from a year earlier.
Does TRIB pay a dividend?
No. Trinity Biotech does not pay a dividend.
How much debt does TRIB have?
Trinity Biotech has $137.98M of total debt and $5.14M of cash and equivalents, a net debt position of $132.84M.
TRIB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors